Karuna Therapeutics, Inc. hopes to raise at least $600m on the back of better-than-expected Phase III efficacy data for its novel therapy for schizophrenia that have set the product on a path to a US regulatory filing mid-next year.
The M1/M4-preferring muscarinic receptor agonist candidate, KarXT (xanomeline-trospium), has achieved positive results in a second Phase III trial, EMERGENT-2, meeting its
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?